Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of miRNA 371 in Patients With Germ Cell Tumors
NCT04435756 · View on ClinicalTrials.gov ↗
Study Summary
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.
Conditions Studied
Interventions
- OTHER Biomarker Analysis
- PROCEDURE Blood Product Collection
Study Locations (20)
California
- Kaiser Permanente-Anaheim — Anaheim
- Kaiser Permanente-Deer Valley Medical Center — Antioch
- PCR Oncology — Arroyo Grande
- Kaiser Permanente-Baldwin Park — Baldwin Park
- Kaiser Permanente-Bellflower — Bellflower
- Keck Medicine of USC Buena Park — Buena Park
- Epic Care-Dublin — Dublin
- Kaiser Permanente Dublin — Dublin
- Bay Area Breast Surgeons Inc — Emeryville
- Epic Care Partners in Cancer Care — Emeryville
- Kaiser Permanente-Fontana — Fontana
- Kaiser Permanente-Fremont — Fremont
- Fresno Cancer Center — Fresno
- Kaiser Permanente-Fresno — Fresno
Arizona
- Banner MD Anderson Cancer Center — Gilbert
- Kingman Regional Medical Center — Kingman
- University of Arizona Cancer Center-Orange Grove Campus — Tucson
- Banner University Medical Center - Tucson — Tucson
- University of Arizona Cancer Center-North Campus — Tucson
Arkansas
- Mercy Hospital Fort Smith — Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 956 participants |
| Start Date | 2020-07-28 |
| Est. Completion | 2028-01-01 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04435756
The ClinicalTrials.gov registry entry for NCT04435756 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 956 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 7 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 2 interventions — of which Biomarker Analysis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04435756 reports 20 study locations spanning 3 distinct geographic areas — top geographies include California, Arizona, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04435756 about?
NCT04435756 is a clinical study titled "A Study of miRNA 371 in Patients With Germ Cell Tumors". This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back...
What is the current status of trial NCT04435756?
This trial is currently active not recruiting. The enrollment target is 956 participants. The study started on 2020-07-28. Estimated completion is 2028-01-01.
What conditions does trial NCT04435756 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Seminoma, Metachronous Malignant Neoplasm, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04435756?
The interventions under investigation include: Biomarker Analysis (OTHER), Blood Product Collection (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04435756?
This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04435756 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.